Lantheus Holdings, Inc. (NASDAQ:LNTH) expands its Alzheimer’s diagnostics capabilities with the acquisition of Life Molecular Imaging Limited. Despite recent stock declines, analysts maintain a Buy rating, projecting an 8.36% EPS growth in the next 5 years. The company specializes in radiopharmaceuticals and diagnostic imaging, emphasizing precision diagnostics and radiotherapeutics for oncology and cardiology.

Read more at Yahoo Finance: Lantheus Holdings Expands Alzheimer’s Diagnostics Despite Recent Stock Dip